Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO) in a research report released on Thursday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Stock Down 13.5 %

NASDAQ:ONVO opened at $2.37 on Thursday. Organovo has a twelve month low of $2.14 and a twelve month high of $21.96. The stock’s 50-day simple moving average is $4.97 and its 200 day simple moving average is $5.13. The firm has a market capitalization of $4.03 million, a PE ratio of -2.79 and a beta of 0.45.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.24. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. On average, analysts anticipate that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.